International Journal of Gynecological Cancer

Article	Citations
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma	972
Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850)	235
SUCCOR study: an international European cohort observational study comparing minimally invasive surgery versus open abdominal radical hysterectomy in patients with stage IB1 cervical cancer	177
PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer	157
ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer – Update 2023*	115
ConCerv: a prospective trial of conservative surgery for low-risk early-stage cervical cancer	90
Clear cell carcinoma of the ovary: a clinical and molecular perspective	87
Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy	86
Surgical versus clinical staging prior to primary chemoradiation in patients with cervical cancer FIGO stages IIB–IVA: oncologic results of a prospective randomized international multicenter (Uterus-1	71
ESGO/ISUOG/IOTA/ESGE Consensus Statement on pre-operative diagnosis of ovarian tumors	66
Refining adjuvant treatment in endometrial cancer based on molecular features: the RAINBO clinical trial program	63
Human papillomavirus-independent cervical cancer	57
Evaluating meaningful levels of financial toxicity in gynecologic cancers	53
Management of pregnancy in women with cancer	52
European Society of Gynaecological Oncology guidelines for the peri-operative management of advanced ovarian cancer patients undergoing debulking surgery	50
Global challenges of radiotherapy for the treatment of locally advanced cervical cancer	48
Enhanced Recovery After Surgery (ERAS) in gynecologic oncology: an international survey of peri-operative practice	47
Uterine serous carcinoma: key advances and novel treatment approaches	46
European Society of Gynaecological Oncology Guidelines for the Management of Patients with Vulvar Cancer - Update 2023	45
ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA–MONO) and rucaparib in combination with nivolumab (ATHENA–COMBO) as maintenance treatment follo	44
Advances in immunotherapy for cervical cancer: recent developments and future directions	42
p53abn Endometrial Cancer: understanding the most aggressive endometrial cancers in the era of molecular classification	42
Ovarian cancer predisposition beyond BRCA1 and BRCA2 genes	40
SUCCOR cone study: conization before radical hysterectomy	40
Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001	38

Ovarian sex cord-stromal tumors: an update on clinical features, molecular changes, and management	36
Decrease in gynecological cancer diagnoses during the COVID-19 pandemic: an Austrian perspective	35
Development of a surgical competency assessment tool for sentinel lymph node dissection by minimally invasive surgery for endometrial cancer	34
ATARI trial: ATR inhibitor in combination with olaparib in gynecological cancers with ARID1A loss or no loss (ENGOT/GYN1/NCRI)	33
Reduced lymphedema after sentinel lymph node biopsy versus lymphadenectomy for endometrial cancer	31
Laparoscopic sentinel node mapping with intracervical indocyanine green injection for endometrial cancer: the SENTIFAIL study – a multicentric analysis of predictors of failed mapping	31
The increasing incidence of stage IV cervical cancer in the USA: what factors are related?	29
Ultrastaging methods of sentinel lymph nodes in endometrial cancer – a systematic review	28
Preventing Ovarian Cancer through early Excision of Tubes and late Ovarian Removal (PROTECTOR): protocol for a prospective non-randomised multi-center trial	28
Pre-operative neoadjuvant chemotherapy cycles and survival in newly diagnosed ovarian cancer: what is the optimal number? A Memorial Sloan Kettering Cancer Center Team Ovary study	28
Incidence, prevalence, and factors associated with lymphedema after treatment for cervical cancer: a systematic review	27
Imaging modalities in pregnant cancer patients	27
Outcomes of women treated with progestin and metformin for atypical endometrial hyperplasia and early endometrial cancer: a systematic review and meta-analysis	26
Survival after minimally invasive surgery in early cervical cancer: is the intra-uterine manipulator to blame?	25
Exploring international differences in ovarian cancer treatment: a comparison of clinical practice guidelines and patterns of care	25
Neoadjuvant chemotherapy followed by surgery in cervical cancer: past, present and future	25
Role of adjuvant therapy after radical hysterectomy in intermediate-risk, early-stage cervical cancer	24
Health-related quality of life among cervical cancer patients in India	24
Updates in the treatment of vaginal cancer	24
Endometrial carcinosarcoma	23
Sentinel lymph node biopsy versus pelvic lymphadenectomy in early-stage cervical cancer: a multi-center randomized trial (PHENIX/CSEM 010)	23
Cost-effectiveness of robotic hysterectomy versus abdominal hysterectomy in early endometrial cancer	23
A novel algorithm to implement the molecular classification according to the new ESGO/ESTRO/ESP 2020 guidelines for endometrial cancer	22
Impact of hypoxia on cervical cancer outcomes	22
Standard ultrastaging compared to one-step nucleic acid amplification (OSNA) for the detection of sentinel lymph node metastases in early stage cervical cancer	22
Sentinel lymph node mapping versus sentinel lymph node mapping with systematic lymphadenectomy in endometrial cancer: an open-label, non-inferiority, randomized trial (ALICE trial)	22
Fertility sparing surgery for patients with FIGO stage I clear cell ovarian carcinoma: a database analysis and systematic review of the literature	22
The European Society of Gynaecological Oncology (ESGO), the International Society for the Study of Vulvovaginal Disease (ISSVD), the European College for the Study of Vulval Disease (ECSVD), and the E	21
Proportions and incidence of locally advanced cervical cancer: a global systematic literature review	21
Transgender patients: considerations for routine gynecologic care and cancer screening	21
Oxidative damage and antioxidants in cervical cancer	21
A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovar	20
ICON 9—an international phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian ca	20
Magnetic resonance imaging-radiomics in endometrial cancer: a systematic review and meta-analysis	20
Updates on cervical cancer prevention	20
Immunotherapy in endometrial cancer	20
A phase III randomized clinical trial comparing sentinel node biopsy with no retroperitoneal node dissection in apparent early-stage endometrial cancer – ENDO-3: ANZGOG trial 1911/2020	20
Not immune to inequity: minority under-representation in immunotherapy trials for breast and gynecologic cancers	19
The European Society of Gynaecological Oncology (ESGO), the International Society for the Study of Vulvovaginal Disease (ISSVD), the European College for the Study of Vulval Disease (ECSVD) and the Eu	19
Endometrial Cancer Lymphadenectomy Trial (ECLAT) (pelvic and para-aortic lymphadenectomy in patients with stage I or II endometrial cancer with high risk of recurrence; AGO-OP.6)	19
Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study	19
Urinary diversion after pelvic exenteration for gynecologic malignancies	19
Oncological outcomes of laparoscopic radical hysterectomy versus radical abdominal hysterectomy in patients with early-stage cervical cancer: a multicenter analysis	18
ADAGIO: a phase IIb international study of the Wee1 inhibitor adavosertib in women with recurrent or persistent uterine serous carcinoma	18
The role of hyperthermia in the treatment of locally advanced cervical cancer: a comprehensive review	18
A systematic review and meta-analysis of sarcopenia as a prognostic factor in gynecological malignancy	18
Enhanced recovery after surgery protocols improve time to return to intended oncology treatment following interval cytoreductive surgery for advanced gynecologic cancers	17
Human epidermal growth factor receptor-2 (HER2) is a potential therapeutic target in extramammary Paget’s disease of the vulva	17
Long-term survival outcomes in high-risk endometrial cancer patients undergoing sentinel lymph node biopsy alone versus lymphadenectomy	17
Fertility preservation in patients with BRCA mutations or Lynch syndrome	17

Postpartum breast cancer: mechanisms underlying its worse prognosis, treatment implications, and fertility preservation	17
Neoadjuvant chemotherapy prior to fertility-sparing surgery in cervical tumors larger than 2 cm: a systematic review on fertility and oncologic outcomes	17
British Gynaecological Cancer Society/British Association of Gynaecological Pathology consensus for germline and tumor testing for BRCA1/2 va	17
Poly (ADP-ribose) polymerase inhibitors (PARPi) in ovarian cancer: lessons learned and future directions	16
Enhanced recovery after minimally invasive gynecologic oncology surgery to improve same day discharge: a quality improvement project	16
Gynecologic cancer surveillance in the era of SARS-CoV-2 (COVID-19)	16
Role of minimally invasive secondary cytoreduction in patients with recurrent ovarian cancer	16
Ovarian transposition in patients with cervical cancer prior to pelvic radiotherapy: a systematic review	16
Management of oligometastatic ovarian cancer recurrence during PARP inhibitor maintenance	16
BRCAtesting in women with high-grade serous ovarian cancer: gynecologic oncologist-initiated testing compared with genetics referral	15
European Society of Gynaecological Oncology quality indicators for the surgical treatment of endometrial carcinoma	15
Management of menopausal symptoms and ovarian function preservation in women with gynecological cancer	15
Survival outcomes after delayed cytoreduction surgery following neoadjuvant chemotherapy in advanced epithelial ovarian cancer	15
Long-term quality of life outcomes of women treated for early-stage endometrial cancer	15
Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician’s choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for plati	15
Anatomical distribution of sentinel lymph nodes in patients with endometrial cancer: a multicenter study	15
Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study	15
Asbestos and ovarian cancer: examining the historical evidence	15
Fertility and pregnancy outcome in gestational trophoblastic disease	15
A randomized phase III trial of adjuvant chemotherapy versus concurrent chemoradiotherapy for postoperative cervical cancer: Japanese Gynecologic Oncology Group study (JGOG1082)	14
Refusal of surgery and survival outcomes in endometrial cancer	14
Quality is more important than quantity: pre-operative sarcopenia is associated with poor survival in advanced ovarian cancer	14
Use of bevacizumab before or after radiotherapy increases the risk of fistula formation in patients with cervical cancer	14
Image-guided brachytherapy in cervical cancer including fractionation	14
Adjuvant chemoradiation associated with improved outcomes in patients with microsatellite instability-high advanced endometrial carcinoma	14
Oncological and obstetrical outcomes after neo-adjuvant chemotherapy followed by fertility-sparing surgery in patients with cervical cancer ≥2 cm	13
Low-grade serous ovarian cancer: expert consensus report on the state of the science	13
Oncologic and obstetric outcomes after simple conization for fertility-sparing surgery in FIGO 2018 stage IB1 cervical cancer	13
The effect of complete surgical staging and adjuvant chemotherapy on survival in stage I, grade 1 and 2 endometrioid ovarian carcinoma	13
Cervical conization and lymph node assessment for early stage low-risk cervical cancer	13
Role of predictive markers for severe postoperative complications in gynecological cancer surgery: a prospective study (RISC-Gyn Trial)	13
Preoperative neutrophil-to-lymphocyte ratio predicts 30 day postoperative morbidity and survival after primary surgery for ovarian cancer	13
ESGO/ESHRE/ESGE Guidelines for the fertility-sparing treatment of patients with endometrial carcinoma	13
Proof-of-concept randomized phase II non-inferiority trial of simple versus type B2 hysterectomy in early-stage cervical cancer ≤2 cm (LESSER)	13
FIGO 2023 endometrial cancer staging: too much, too soon?	12
Predictive role of serum cholesterol and triglycerides in cervical cancer survival	12
Trends and survival outcomes of robotic, laparoscopic, and open surgery for stage II uterine cancer	12
CERVANTES: an international randomized trial of radical surgery followed by adjuvant (chemo) radiation versus no further treatment in patients with early-stage, intermediate-risk cervical cancer (CEEG	12
Psychosexual morbidity in women with ovarian cancer	12
Treatment of bulky lymph nodes in locally advanced cervical cancer: boosting versus debulking	12
Niraparib maintenance in frontline management of ovarian cancer: a cost effectiveness analysis	12
Biomarker-driven therapy in endometrial cancer	12
Gastric-type adenocarcinoma of the cervix in patients with Peutz-Jeghers syndrome: a systematic review of the literature with proposed screening guidelines	12
Physical activity levels among ovarian cancer survivors: a prospective longitudinal cohort study	12
Simplified anatomical nomenclature of lateral female pelvic spaces	12
Adjuvant treatment after radical surgery for cervical cancer with intermediate risk factors: is it time for an update?	12
ATOMICC trial: a randomized, open-label, phase II trial of anti-PD1, dostarlimab, as maintenance therapy for patients with high-risk locally advanced cervical cancer after chemoradiation	12
Impact of geography and travel distance on outcomes in epithelial ovarian cancer: a national cancer database analysis	11
Quality assurance in human papillomavirus testing for primary cervical screening	11
Role of adjuvant radiation therapy after radical hysterectomy in patients with stage IB cervical carcinoma and intermediate risk factors	11
Conization and lymph node evaluation as a fertility-sparing treatment for early stage cervical cancer	11
Oncologic outcomes of minimally invasive versus open radical hysterectomy for early stage cervical carcinoma and tumor size <2 cm: a systematic review and meta-analysis	11
Longitudinal patient-reported outcomes and restrictive opioid prescribing after minimally invasive gynecologic surgery	11
Role of radical hysterectomy in patients with early-stage high-grade neuroendocrine cervical carcinoma: a NeCTuR study	11
Palliative care referral patterns and measures of aggressive care at the end of life in patients with cervical cancer	11
Race-driven survival differential in women diagnosed with endometrial cancers in the USA	11
The role of radiotherapy in ovarian cancer	11
Uterine transposition after radical trachelectomy	11
Integrating antibody drug conjugates in the management of gynecologic cancers	11
Uterine transposition for gynecological cancers	10
The impact of sentinel lymph node sampling versus traditional lymphadenectomy on the survival of patients with stage IIIC endometrial cancer	10
Ovarian cancer recurrence detection may not require in-person physical examination: an MSK team ovary study	10
The application of metabolomics in ovarian cancer management: a systematic review	10
TRAINING-Ovary 01 (connecTed pRehabiliAtIoN pelvIc caNcer surGery): multicenter randomized study comparing neoadjuvant chemotherapy for patients managed for ovarian cancer with or without a connected	10
Transfusion use and effect on progression-free, overall survival, and quality of life in upfront treatment of advanced epithelial ovarian cancer: evaluation of the European Organization for Research a	10
Metronomic oral cyclophosphamide in relapsed ovarian cancer	10
Avascular spaces in radical hysterectomy	10
Minimally invasive versus open pelvic exenteration in gynecological malignancies: a propensity-matched survival analysis	10
Prognostic markers of inflammation in endometrioid and clear cell ovarian cancer	10
Mismatch repair deficiency, next-generation sequencing-based microsatellite instability, and tumor mutational burden as predictive biomarkers for immune checkpoint inhibitor effectiveness in frontline	10
Molecular subclassification of vulvar squamous cell carcinoma: reproducibility and prognostic significance of a novel surgical technique	10
Safety and management of niraparib monotherapy in ovarian cancer clinical trials	10
FIGO 2018 stage IB endocervical adenocarcinomas: an international study of outcomes informed by prognostic biomarkers	10
Incorporating molecular profiling into endometrial cancer management requires prospective studies	10
Poly (ADP-ribose) polymerase (PARP) inhibitor regimens for ovarian cancer in phase III randomized controlled trials: a network meta-analysis	10
Detection of microRNA in urine to identify patients with endometrial cancer: a feasibility study	10
Endometrial stripe thickness: a preoperative marker to identify patients with endometrial intraepithelial neoplasia who may benefit from sentinel lymph node mapping and biopsy	10
Impact of hysteroscopy on course of disease in high-risk endometrial carcinoma	10
Role of vaginal brachytherapy boost following adjuvant external beam radiotherapy in cervical cancer: Turkish Society for Radiation Oncology Gynecologic Group Study (TROD 04-002)	9
ESGO/ESTRO quality indicators for radiation therapy of cervical cancer	9

Fertility sparing surgery in sex-cord stromal tumors: oncological and reproductive outcomes	9
The Cervical Cancer Research Network (Gynecologic Cancer InterGroup) roadmap to expand research in low- and middle-income countries	9
Inside the war: life in Ukraine	9
Efficacy and safety of PARP inhibitors in elderly patients with advanced ovarian cancer: a systematic review and meta-analysis	9
Adjuvant treatment improves overall survival in women with high-intermediate risk early-stage endometrial cancer with lymphovascular space invasion	9
Peritoneal carcinomatosis after minimally invasive surgery versus open radical hysterectomy: systematic review and meta-analysis	9
Advances in immunotherapy in cervical cancer	9
Sentinel lymph node detection in early-stage ovarian cancer: a systematic review and meta-analysis	9
Treatment of ovarian clear cell carcinoma with immune checkpoint blockade: a case series	9
Efficacy and safety of stereotactic body radiotherapy (SBRT) in oligometastatic/persistent/recurrent ovarian cancer: a prospective, multicenter phase II study (MITO-RT3/RAD)	9
Role of stereotactic body radiotherapy in gynecologic radiation oncology	9
TUBectomy with delayed oophorectomy as an alternative to risk-reducing salpingo-oophorectomy in high-risk women to assess the safety of prevention: the TUBA-WISP II study protocol	9
The shift from inpatient to outpatient hysterectomy for endometrial cancer in the United States: trends, enabling factors, cost, and safety	9
Radical trachelectomy	9
CHRONO: randomized trial of the CHROnology of surgery after Neoadjuvant chemotherapy for Ovarian cancer	9
Novel therapeutics in low-grade serous ovarian cancer	9
Primary mucinous ovarian cancer: options for surgery and chemotherapy	9
Fertility-sparing surgery for patients with stage IC2 or IC3 epithelial ovarian carcinoma: any evidence of safety?	8
Human papillomavirus (HPV) vaccination: a call for action in Italy	8
Surveillance alone in stage I malignant ovarian germ cell tumors: a MITO (Multicenter Italian Trials in Ovarian cancer) prospective observational study	8
Prognostic factors in locally advanced cervical cancer with pelvic lymph node metastasis	8
Oncologic and obstetrical outcomes after fertility-preserving retreatment in patients with recurrent atypical endometrial hyperplasia and endometrial cancer	8
Uterine transposition for fertility and ovarian function preservation after radiotherapy	8
Gender imbalance in gynecologic oncology authorship and impact of COVID-19 pandemic	8
Survival impact of histological response to neoadjuvant chemotherapy according to number of cycles in patients with advanced ovarian cancer	8
Brachytherapy or external beam radiotherapy as a boost in locally advanced cervical cancer: a Gynaecology Study Group in the Italian Association of Radiation and Clinical Oncology (AIRO) review	8
Utilization and outcomes of adjuvant systemic chemotherapy alone in high risk, early stage cervical cancer in the United States	8
LION-PAW (lymphadenectomy in ovarian neoplasm) sexual function assessment: a prospective sub-study of the LION trial	8
Outcomes of comprehensive lymphadenectomy for patients with advanced stage ovarian carcinoma and rare histologic sub-types	8
Radical hysterectomy in early cervical cancer in Europe: characteristics, outcomes and evaluation of ESGO quality indicators	8
Risk of second malignancy in patients with ovarian clear cell carcinoma	8
PARa-aOrtic LymphAdenectomy in locally advanced cervical cancer (PAROLA trial): a GINECO, ENGOT, and GCIG study	8
Safety and activity of anti-mesothelin antibody–drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose	8
Impact of SARS-CoV-2 on training and mental well-being of surgical gynecological oncology trainees	8
Pre-operative surgical algorithm: sentinel lymph node biopsy as predictor of parametrial involvement in early-stage cervical cancer	8
Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3	8
Uterine transposition in a pre-pubertal patient	8
Role of inhibin B in detecting recurrence of granulosa cell tumors of the ovary in postmenopausal patients	8
Long-term response to olaparib inBRCA1-related ovarian cancer with brain metastases	8
Sleep and gynecological cancer outcomes: opportunities to improve quality of life and survival	8
Across barriers: poly ADP-ribose polymerase inhibitors beyond progression in high grade serous ovarian cancer with brain metastases	8
Adherence to European ovarian cancer guidelines and impact on survival: a French multicenter study (FRANCOGYN)	8
Update in the molecular classification of endometrial carcinoma	8
Adjuvant brachytherapy for FIGO stage I serous or clear cell endometrial cancer	8
Myeloid neoplasms post PARP inhibitors for ovarian cancer	7
Consensus on the Gemelli terminology of surgical anatomy for radical hysterectomy	7
Overcoming PARP inhibitor resistance in ovarian cancer	7
Combining cervical cancer screening for mothers with schoolgirl vaccination during human papillomavirus (HPV) vaccine implementation in South Africa: results from the VACCS1 and VACCS2 trials	7
DUETTE: a phase II randomized, multicenter study to investigate the efficacy and tolerability of a second maintenance treatment in patients with platinum-sensitive relapsed epithelial ovarian cancer,	7
Tumor total lesion glycolysis and number of positive pelvic lymph nodes on pretreatment positron emission tomography/computed tomography (PET/CT) predict survival in patients with locally advanced cer	7
Quality of training in cervical cancer radical surgery: a survey from the European Network of Young Gynaecologic Oncologists (ENYGO)	7
Impact of surgical approach on prevalence of positive peritoneal cytology and lymph-vascular invasion in patients with early-stage endometrial carcinoma: a National Cancer Database study	7
Gynecologic oncologists in surgery for placenta accreta spectrum: a survey for practice, experience, and interest	7
New therapies for clear cell ovarian carcinoma	7
Transvaginal natural orifice transluminal endoscopic surgery (VNOTES) total retroperitoneal sentinel lymph node biopsy for an endometrial cancer patient with prior colon cancer surgery	7
Lymphadenectomy for early-stage mucinous ovarian carcinoma	7
ESTRO/ESGO/SIOPe Guidelines for the management of patients with vaginal cancer	7
Improving Endometrial cancer assessment by combining the new techniqUe of GENomic profiling with surgical Extra uterIne disEase assessment (EUGENIE)	7
Clinicopathologic characteristics, oncologic outcomes, and prognostic factors in neuroendocrine cervical carcinoma: a Neuroendocrine Cervical Tumor Registry study	7
Short- and long-term outcomes for single-port risk-reducing salpingo-oophorectomy with and without hysterectomy for women at risk for gynecologic cancer	7
Report from the European Society of Gynaecological Oncology (ESGO) 2020 State-of-the-Art Virtual Meeting	7
Fertility considerations prior to conservative management of gynecologic cancers	7
Outcomes of patients with cervical cancer treated with low- or high-dose rate brachytherapy after concurrent chemoradiation	7
Limited frequency of malignant change in lobular endocervical glandular hyperplasia	7
Laparoscopic management of advanced epithelial ovarian cancer after neoadjuvant chemotherapy: a phase II prospective multicenter non-randomized trial (the CILOVE study)	7
Central radiology assessment of the randomized phase III open-label OVHIPEC-1 trial in ovarian cancer	7
Placenta accreta spectrum: a non-oncologic challenge for gynecologic oncologists	7
Survival after sentinel lymph node biopsy for early cervical cancers: a systematic review and meta-analysis	7
Disparities in gynecologic cancer incidence, treatment, and survival: a narrative review of outcomes among black and white women in the United States	7
Disparity of ovarian cancer survival between urban and rural settings	7
Nerve-sparing radical hysterectomy—Muallem technique with explanation of parametrium and paracolpium anatomy	7
Combination of weekly paclitaxel-carboplatin plus standard bevacizumab as neoadjuvant treatment in stage IB–IIB cervical cancer	7
Early referral to a palliative team improves end-of-life care among gynecological cancer patients: a retrospective, population-based study	7
Oncologic outcomes of surgical para-aortic lymph node staging in patients with advanced cervical carcinoma undergoing chemoradiation	7
Stereotactic body radiotherapy in oligometastatic cervical cancer (MITO-RT2/RAD study): a collaboration of MITO, AIRO GYN, and MaNGO groups	7
Oncological and reproductive outcomes for gonadotropin-releasing hormone agonist combined with aromatase inhibitors or levonorgestrel-releasing intra-uterine system in women with endometrial cancer or	6
BIOPSAR study: ultrasound-guided pre-operative biopsy to assess histology of sarcoma-suspicious uterine tumors: a new study protocol	6
Stage IVA cervical cancer: outcomes of disease related complications and treatment	6
Cervical cancer in Eastern Europe: review and proceedings from the Cervical Cancer Research Conference	6
22nd meeting of the European Society of Gynaecological Oncology (ESGO 2021) report	6
Efficacy of pre-operative pharmacologic thromboprophylaxis on incidence of venous thromboembolism following major gynecologic and gynecologic oncology surgery: a systematic review and meta-analysis	6
Post-operative residual disease and number of cycles of neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma	6
HrHPV testing vs liquid-based cytology in cervical cancer screening among women aged 50 and older: a prospective study	6
Mirvetuximab soravtansine-gynx: first antibody/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancer	6
Impact of residual disease at interval debulking surgery on platinum resistance and patterns of recurrence for advanced-stage ovarian cancer	6
Employment disruption among women with gynecologic cancers	6
Association between time to diagnosis, time to treatment, and ovarian cancer survival in the United States	6
Overall survival after surgical staging by lymph node dissection versus sentinel lymph node biopsy in endometrial cancer: a national cancer database study	6
Prognostic value of isolated tumor cells in sentinel lymph nodes in low risk endometrial cancer: results from an international multi-institutional study	6
Predictive factors of sentinel lymph node failed mapping in endometrial carcinoma patients: a systematic review and meta-analysis	6
CINOVA: a phase II study of CPC634 (nanoparticulate docetaxel) in patients with platinum resistant recurrent ovarian cancer	6
BRCAstatus and platinum sensitivity in advanced ovarian cancer according to Chemotherapy Response Score	6
Targeted therapy for mucinous ovarian carcinoma: evidence from clinical trials	6
Impact of clinical factors and surgical outcome on long-term survival in high-grade serous ovarian cancer: a multicenter analysis	6
Transdiaphragmatic and transxiphoid cardiophrenic lymph node resection step-by-step in advanced ovarian cancer	6